instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
The city school systems in Albertville, Boaz and Guntersville have joined the Cullman County and Marshall County system in shutting down until next week. State statistics show Marshall County is the largest system affected by the illness with 5,468 students in kindergarten through the 12th grade. Marshall County plans to resume classes on Tuesday; the others return on Monday. Gov. Kay Ivey declared a flu emergency earlier this month because of an outbreak of the illness. State Health Department officials have said they are investigating more than 50 deaths potentially linked to a flu outbreak statewide, and the agency has been special clinics to vaccinate people against the disease.
answer:
5 Alabama school systems closed because of flu.

question:
The coffin, one of three brought the same morning, came hours after officials said 13 elderly residents had diedin the home since March 11 and that more than 80 others were believedto have the coronavirus. Most of the dead were aged over 90, an official at the regional healthauthority told Reuters. Authorities have not been able to establish the cause of death in most cases. "The deliveries are non-stop. There are going to be more on Monday," the delivery man said as he removed the casket's plastic cover. The facility in Paris' 12th district is one of several care homes across France to be hit by thecoronavirus outbreak. There have been large numbers of deaths too at retirement homes in Italy and Spain. Almost 1 million people reside in care homes in France. In the Paris region alone, the regional health authority saysthat 148 out of the 700 homes in its network have reported coronavirus cases and at least 61 residents have died. The Rothschild Foundation home in Paris was put on red alerton March 6 as the epidemic took hold. Staff were givenstricter entry protocols, told to wear gloves and masks atall times, disinfect everything and urged to isolate suspectedcases. "We knew it was coming. The first two people with symptoms weretested and then isolated, but once it was established that theyhad it, we stopped testing because it's then a cluster. Youcan't allow it to spread," said a health worker aware of the situation. Since then all residents have been confinedto their rooms where they are fed and washed. But whilethe number of new cases has slowed, the deaths continue. Executives at the home did not respond to Reuters phone calls seeking detailed information about what was happening in the home, but in a brief exchange, one executive described the situation at the facility as very tough. France's official coronavirus death toll stands at some 1,100 people, but that does not include deaths outside hospitals. Fatalities in nursing homes have surged recently with dozens of deaths reported across the country. "When you don't have enough staff andequipment and need to care for fragile people then itleads to a high mortality rate. When it enters into a nursinghome, you are going to see 20% of residents die," saidThierry Amouroux, a nurse and representative at the NationalUnion for Professional Nurses. Seniorcare home representatives warned the Health Minister in a letter seen by Reutersthat workers in the homes needed 500,000 masks. At least 100,000 people could die if the situation was not brought under control, they wrote. Jerome Larche, an intensive care doctor in Montpellier, whosecompany also operates care homes, said it was critical to avoid mass contaminations. "Mostof the residents can't be taken to intensive careso if there are contaminations, there will be deaths," Larche said. At the Bergeron-Grenier care home in western France, half of carershave opted to confine themselves within the home to reduce the risk of spreading the coronavirus. "Before, we were always afraid. No matter how careful wewere, we still had this fear of infecting our residents bybringing the virus from outside," administrative assistantPatricia Vandebrouck said.
answer:
'Delivering coffins non-stop': coronavirus stalks a Paris nursing home.

question:
The news is a boost for the Spanish biotech company, which already sells Yondelis as a treatment for soft tissue sarcoma, a rare disease, and now hopes to address a much bigger commercial opportunity. Bradley Monk, an oncologist from the University of California Irvine Medical Center who led a Phase III trial of the drug, said Yondelis could be added to a short list of active drug therapies for recurrent ovarian cancer. "These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," Monk said in a statement. "This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much-needed option." Zeltia's drug, which it is developing with Johnson & Johnson, is unusual in that it is a synthetic version of a compound isolated from a type of sea squirt, a tubular marine animal. It works by binding to the DNA of cancer cells and blocking their ability to multiply. At 1445 GMT, Zeltia shares were down 5.4 percent at 5.43 euros, regaining ground after a low of 4.99 euros, while Spain's IBEX-35 blue chip index dropped 4.1 percent. "The stock's had a good run. This news is already in the price," a Madrid-based trader said. The Spanish company had already announced that Yondelis, its first product to reach the market, had shown positive results in the pivotal trial. But the actual results of the study, involving 672 women whose ovarian cancer had progressed after first-line treatment, were only disclosed at the annual meeting of the European Society of Medical Oncology (ESMO) in Stockholm. Monk said the results showed those women given a combination of Yondelis and Johnson & Johnson's chemotherapy drug Doxil had no progression of their cancer for an average of 7.3 months, against 5.8 months for women treated only with Doxil. In the case of women who had relapsed more than six months after getting first-line therapy, the median progression-free time was 9.2 months with Yondelis versus 7.5 months. In common with other anti-cancer agents, this suggests Yondelis is most active in patients who have gone a long time since receiving initial chemotherapy treatment. Zeltia plans to submit Yondelis for approval in Europe in the fourth quarter of this year. Johnson & Johnson is expected to file in the United States by the end of the year as well. The Spanish group has previously estimated that peak sales of Yondelis for ovarian cancer could be around 300 million euros ($420 million) in the European Union alone. Sales of the drug as a treatment for soft tissue sarcoma are forecast to be about 30 million euros this year. Yondelis, whose generic name is trabectedin, is currently approved for soft tissue sarcoma in Europe but not the U.S. The product is also being studied in smaller, Phase II trials for prostate, breast and childhood cancers.
answer:
Zeltia drug delays progression of ovarian cancer.